Clinical Trials Logo

Intermediate Uveitis clinical trials

View clinical trials related to Intermediate Uveitis.

Filter by:

NCT ID: NCT04126850 Not yet recruiting - Behçet Disease Clinical Trials

Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

Start date: November 1, 2019
Phase:
Study type: Observational

This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis

NCT ID: NCT02879084 Completed - Anterior Uveitis Clinical Trials

Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis

Start date: August 2016
Phase:
Study type: Observational

This study investigates the variations in the retinal nerve fiber layer (RNFL) thickness during uncomplicated anterior and intermediate uveitis, respectively. The objectives are to 1 ) confirm the RNFL thickening during an uncomplicated anterior uveitis as described in the literature, 2) measure the RNFL thickness during an uncomplicated intermediate uveitis specifically and 3) describe the variation in time of RNFL thickness during the two types of uveitis.

NCT ID: NCT02764697 Completed - Uveitis Clinical Trials

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

Start date: June 30, 2016
Phase: Phase 4
Study type: Interventional

Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision. This inflammation, is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.

NCT ID: NCT02746991 Completed - Panuveitis Clinical Trials

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

Start date: June 2, 2015
Phase: Phase 3
Study type: Interventional

Phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye. Patients will be randomized to receive either a sham injection or the FAI insert and will be observed for three years following treatment.

NCT ID: NCT01789320 Completed - Uveitis Clinical Trials

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

NCT ID: NCT01717170 Active, not recruiting - Posterior Uveitis Clinical Trials

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

STOP-Uveitis
Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or panuveitis.

NCT ID: NCT01280669 Withdrawn - Uveitis Clinical Trials

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

SAVE-2
Start date: September 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out about the safety and effectiveness of two different doses the study drug, sirolimus, administered intravitreally in patients with uveitis. The potential effectiveness of sirolimus can be utilized to control inflammation in uveitis and yet avoid the potential complications that are usually associated with the systemic use of the drug and other immunomodulatory therapies. In this study, the investigators will administer sirolimus inside the eye (intravitreally) in one of two doses (440mcg/mcL or 880mcg/mcL). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.

NCT ID: NCT00908466 Completed - Uveitis Clinical Trials

Sirolimus as Therapeutic Approach to Uveitis

SAVE
Start date: July 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential complications of systemic use of the drug. In this study, the investigators will administer sirolimus either around (subconjunctival injection) or inside the eye (intravitreal injection). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.

NCT ID: NCT00570830 Completed - Posterior Uveitis Clinical Trials

Retisert and Cataract Surgery in Patients With Severe Uveitis

Start date: September 2006
Phase: N/A
Study type: Interventional

To review chart data at the Duke Eye Center and determined whether a 3-year fluocinolone acetonide sustained drug delivery system (FA) safely suppressed postoperative inflammation when combined with phacoemulsification and posterior chamber intraocular lens implantation (phaco/PCIOL) in eyes with severe uveitis.

NCT ID: NCT00333814 Completed - Posterior Uveitis Clinical Trials

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.